Equities Analysts Offer Predictions for ROIV Q3 Earnings

Roivant Sciences Ltd. (NASDAQ:ROIV) – Investment analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for Roivant Sciences in a research report issued to clients and investors on Tuesday, December 3rd. Leerink Partnrs analyst D. Risinger forecasts that the company will earn ($0.22) per share for the quarter. The consensus estimate for Roivant Sciences’ current full-year earnings is ($1.20) per share. Leerink Partnrs also issued estimates for Roivant Sciences’ Q4 2025 earnings at ($0.28) EPS and FY2026 earnings at ($1.03) EPS.

ROIV has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a report on Wednesday, November 13th. Bank of America lifted their price objective on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research report on Wednesday, September 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.93.

Roivant Sciences Price Performance

Shares of ROIV opened at $12.36 on Friday. Roivant Sciences has a 1-year low of $9.48 and a 1-year high of $13.06. The stock has a market cap of $9.00 billion, a price-to-earnings ratio of 2.19 and a beta of 1.25. The firm has a 50 day simple moving average of $11.82 and a 200-day simple moving average of $11.41.

Insider Transactions at Roivant Sciences

In other news, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the completion of the sale, the chief operating officer now owns 617,470 shares in the company, valued at approximately $7,193,525.50. The trade was a 13.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Rakhi Kumar sold 250,000 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $11.89, for a total transaction of $2,972,500.00. Following the sale, the chief accounting officer now directly owns 209,322 shares of the company’s stock, valued at approximately $2,488,838.58. This trade represents a 54.43 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,677,309 shares of company stock worth $43,283,184 in the last three months. Company insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

Several large investors have recently made changes to their positions in ROIV. FMR LLC increased its holdings in Roivant Sciences by 5.6% in the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after purchasing an additional 2,593,910 shares in the last quarter. Rubric Capital Management LP boosted its position in shares of Roivant Sciences by 15.0% in the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock worth $243,110,000 after buying an additional 3,000,000 shares during the period. State Street Corp grew its stake in shares of Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after buying an additional 1,118,561 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Roivant Sciences by 23.2% during the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock valued at $89,400,000 after buying an additional 1,460,205 shares during the period. Finally, DME Capital Management LP lifted its position in Roivant Sciences by 14.8% during the 2nd quarter. DME Capital Management LP now owns 4,810,960 shares of the company’s stock worth $50,852,000 after acquiring an additional 620,470 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.